Shasun NBI LLC www.nanoparticlebiochem.com Shasun NBI LLC is a joint venture between Shasun Pharmaceuticals of Chennai, India, and Nanoparticle Biochem Inc. of Columbia for research and product development of targeted cancer-fighting agents. The company is exploring clinical applications of its lead product, NBI 29, a radioactive gold compound, in treating prostate cancer. The treatment has the potential to shrink the size of tumors prior to surgery, and eradicate some tumors without surgery. Shasun NBI will soon file an application with the U.S. Food & Drug Administration to conduct Phase I clinical trials to determine dose tolerance and therapeutic efficacy in humans.
Tensive Controls email@example.com Tensive Controls is developing an oral melanocortin drug that could reverse cachexia, a wasting condition marked by loss of lean body mass. The company’s product features a patented chemical entity that suppresses the hypertensive effects of melanocortins, improving the effective treatment window for the underlying disease. The work has the potential to become the first FDAapproved drug for cachexia, according to President/ CEO Kenneth Gruber.
John Middleton Leading a company so new it doesn’t have a name yet, veterinarian John Middleton has won a Faculty Innovation Award, granting him a year in the incubator. Middleton’s as-yet-unnamed company will devise innovative medical devices and treatments for the animal health sector. The first product in development is an intramammary injection device to deliver prophylactic or therapeutic products to dairy animals. The device would be useful in the treatment of mastitis, the most common and costly infectious disease of dairy cattle.
Find Out More For more details about the companies in the MU Life Science Business Incubator, go to www.ColumbiaCEO.com. spring 2011
Inside Columbia’s CEO
Published on Mar 15, 2011
Joan Gabel prepares MU business students for a bright future; the Renaissance Awards celebrate local art's biggest fans; and Columbia's busi...